Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

XTENT, Inc. (NASDAQ:XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. XTENT, Inc. (NASDAQ:XTNT) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona. The company will hold a webcast and conference call to review the new CUSTOM III data immediately following the late-breaking session. In addition, two-year CUSTOM I data, previously presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting last October, has been accepted for publication in the May issue of EuroIntervention. Professor Grube, the CUSTOM I principal investigator, has been asked to present the data during a EuroPCR session on the six best papers from EuroIntervention. XTENT is also sponsoring an evening symposium on customizable drug-eluting stents and will exhibit throughout the meeting at booth E11 in the main hall.